Breadcrumb

null Cecilia Costiniuk, MD, MSc

Scientist, RI-MUHC, Glen site

Infectious Diseases and Immunity in Global Health Program

Centre for Translational Biology

Associate Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Infectious Diseases, MUHC

 

Keywords

HIV • HIV reservoirs • chronic lung disease • pulmonary inflammation • pulmonary immunity • vaccine immunogenicity • endocannabinoids

Research Focus

My research focuses on factors associated with accelerated chronic lung disease in HIV infection. Despite the success of antiretroviral therapy (ART), individuals with HIV are at increased risk of chronic lung disease, which cannot be accounted for by smoking alone. My lab examines the lungs as HIV reservoirs and factors within the pulmonary milieu that facilitate HIV persistence and increased chronic lung disease, despite effective ART. Similarly, I examine factors associated with vaccine immunogenicity in people with HIV in order to inform vaccination strategies. These studies are complemented by my work on the expanded endocannabinoid system as a potential target to reduce HIV reservoir sizes, inflammation and ultimately comorbidities.

Selected Publications

Click on Pubmed to see my current publications list

  • Costiniuk CT, Lee T, Singer J, Galipeau Y, McCluskie PS, Arnold A, Langlois MA, Needham J, Jenabian MA, Burchell AN, Samji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HL, Brockman MA, Margolese S, Mandarino E, Samarani S, Lebouché B, Angel JB, Routy JPR, Cooper CL, and Anis AH for the COVAXHIV Study Group. Correlates of breakthrough SARS-CoV2 infections in people with HIV: Results from the CIHR CTN 328 study. Vaccines 2024. Vaccines (Basel). 2024 Apr 23;12(5):447. PMID: 38793698.

  • Costiniuk CT, Singer J, Lee T, Galipeau Y, McCluskie PS, Arnold C, Langlois MA, Needham J, Jenabian MA, Burchell AN, Samji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HR, Brockman MA, Margolese S, Mandarino E, Samarani S, Vulesevic B, Lebouche B, Angel JB, Routy JP, Cooper CL, Anis AH; COVAXHIV Study Group. Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328). AIDS. 2023 Oct 1;37(12):F25-F35. PMID: 37534695.

  • Mboumba Bouassa RS*, Needham J, Singer J, Lee T, Boboeuf F, Samarani S, Del Balso L, Paisible N, Vertgazias C, Sebastiani G, Margolese S, Mandarino E, Klein M, Lebouché B, Cox J, Brouillette MJ, Routy JP, Szabo J, Thomas R, Huchet E, Vigano A, Jenabian MA,, Costiniuk CT. Safety and tolerability of oral cannabinoids in people living with HIV on long-term ART: a randomized, open-label, interventional pilot clinical study (CTN PT028). Biomedicines. 2022 Dec 7;10(12):3168. PMID: 36551926.

  • Wang Z, Jenabian MA, Alexandrova Y*, Pagliuzza A, Olivenstein R, S Samarani, Chomont N, Jenabian MA, Kembel SW, Costiniuk CT. Interplay between the lung microbiome and pulmonary mucosal immunity in people living with HIV on antiretroviral therapy. Viruses. 2022 Oct 29;14(11):2395. doi: 10.3390/v14112395. PMID: 36366495.

  • Costiniuk CT, Nitulescu R, Saneei Z, Wasef N*, Salahuddin S*, Wasef D*, Young J, de Castro C, Routy JP, Lebouche B, Cox J, Smith BM, Ambroise A, Pexos C, Patel M, Szabo J, Haraoui LP, de Pokomandy A, Tsoukas C, Falutz J, LeBlanc R, Giannakis A, Frenette C, Jenabian MA, Bourbeau J, Klein MB. Prevalence and Predictors of Airflow Obstruction in an HIV Tertiary Care Clinic in Montreal, Canada: A Cross Sectional Study HIV Medicine 2019 Jan 8. doi: 10.1111/hiv.12699. PMID: 30620136.